Press Releases

 
Press Releases
  Date Title and Summary View
Mar 23, 2015
HAYWARD, Calif., March 23, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 5,555,556 shares of its common stock, offered at a price of $4.50 per share.  In addition, Anthera has granted the underwriters a 30-day option to purchase up to...
Mar 19, 2015
HAYWARD, Calif., March 19, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced it has received an award from Cystic Fibrosis Foundation Therapeutics Inc. of up to $3 million to support the manufacturing and clinical development of Anthera's novel pancreatic enzyme replacement therapy, Sollpura™ (liprotamase).   C...
Mar 18, 2015
HAYWARD, Calif., March 18, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock, offered at a price of $4.50 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commi...
Mar 17, 2015
HAYWARD, Calif., March 17, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the p...
Mar 16, 2015
HAYWARD, Calif., March 16, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), in collaboration with its partner Zenyaku Kogyo Co., Ltd. today announced that the BRIGHT-SC study of blisibimod in patients with IgA nephropathy (IgAN) should continue to completion as planned. This follows the successful completion of an interim futility...
Mar 16, 2015
HAYWARD, Calif., March 16, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced financial results and an operational update for the fourth quarter and year ended December 31, 2014. Net loss for the fourth quarter and year ended December 31, 2014 was $7.4 million and $29.6 million, respectively, compared to $9.2 ...
Feb 19, 2015
HAYWARD, Calif., Feb. 19, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update on the progress of the Company's development programs at the 35th Annual Cowen & Company Health Care Conference. Anthera will present from 10:00...
Feb 10, 2015
HAYWARD, Calif., Feb. 10, 2015 /PRNewswire/ -- Anthera Pharmaceuticals (NASDAQ: ANTH) today announced that the company has received formal notification from the Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders' equity or maint...
Feb 10, 2015
HAYWARD, Calif., Feb. 10, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted...
Jan 7, 2015
HAYWARD, Calif., Jan. 7, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced the appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer. "We're fortunate to have Klara join our team as we enter this phase of our product development efforts," said Paul F. Truex, Anthera's President...
Page:
1
... NextLast
= add release to Briefcase
JoomShaper